Quick answers
- What is Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate) used for?
- The FDA-approved label (Actonel, Allergan, Inc., February 4, 2026) says: “ACTONEL is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis Treatment to increase bone mass in men with osteoporosis Treatment and prevention of glucocorticoid-induced osteoporosis Treatment of Paget’s disease Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate) have a boxed warning?
- No. None of the 4 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate)?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate) been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate)?
- 2 companies list prescription products of Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate) in the FDA NDC Directory, including Allergan, Inc. and Mylan Pharmaceuticals Inc..
What Risedronate sodium (risedronate sodium hemipentahydrate / risedronate sodium monohydrate) is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ACTONEL is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis Treatment to increase bone mass in men with osteoporosis Treatment and prevention of glucocorticoid-induced osteoporosis Treatment of Paget’s disease Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. …
— FDA label: Actonel, Allergan, Inc., effective February 4, 2026. Read the full label on DailyMed →
The FDA has 4 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 4 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| risedronate sodium hemipentahydrate 129 mg · risedronate sodium monohydrate 21 mg tablet, film coated | Generic | $11.02 per tablet |
| risedronate sodium hemipentahydrate 30.1 mg · risedronate sodium monohydrate 4.9 mg tablet, delayed release | Generic | $31.34 per tablet |
| risedronate sodium hemipentahydrate 30.1 mg · risedronate sodium monohydrate 4.9 mg tablet, delayed release | Brand: Atelvia | $63.81 per tablet |
| risedronate sodium hemipentahydrate 30.1 mg · risedronate sodium monohydrate 4.9 mg tablet, film coated | Generic | $1.47 per tablet |
| risedronate sodium hemipentahydrate 30.1 mg · risedronate sodium monohydrate 4.9 mg tablet, film coated | Brand: Actonel | $81.86 per tablet |
NADAC list of November 4, 2026; these prices took effect between January 21, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Allergan, Inc.3 products
- Mylan Pharmaceuticals Inc.3 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020835 ACTONEL | Apil | March 27, 1998 | 33, latest February 3, 2026 2026: Labeling · 2019: Labeling · 2015: Manufacturing (CMC) |
| NDA022560 ATELVIA | Apil | October 8, 2010 | 9, latest February 3, 2026 2026: Labeling · 2020: Labeling · 2015: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 905024, 905026, 905028, 905030, 905032, 905034, 905041, 905043, 905083, 905084 … (+9) |
|---|---|
| SPL set ID of the quoted label | 24ed00e0-25e2-49a8-97fc-66c1b417dc0b |
| FDA labels (SPL) | 4 |
| FDA applications | NDA020835, NDA022560 |
| Active ingredients (FDA) | RISEDRONATE SODIUM HEMIPENTAHYDRATE / RISEDRONATE SODIUM MONOHYDRATE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Actonel, Allergan, Inc., effective February 4, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →